Clinical Trial Update: A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating B019 Injection in relapsed or refractory B-cell non-Hodgkin lymphoma; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• B019 Injection

Snippet

Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. | Conditions: Relapsed or Refractory B Cell Non Hodgkin Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING